Skip to main content
TipRanks
Go Ultimate75% OFF

Connect Biopharma Holdings (CNTB) Stock Price & Analysis

230 Followers

CNTB Stock Chart & Stats

$0.67$0.09(15.05%)
At close: 4:00 PM EST
$1$2Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.56 - $0.67
52-Week Range
$0.55 - $3.82
Previous Close
$0.58
Volume
N/A
Average Volume (3M)
794.01K
Market Cap
$37.33M
Enterprise Value
$118.77M
Total Cash (Recent Filing)
$31.49M
Total Debt (Recent Filing)
$596.00K
Price to Earnings (P/E)
―
Beta
-0.25
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase 2 COPD Efficacy

The Phase 2 COPD results provide meaningful clinical validation for rademikibart, including lower treatment failures, exacerbations, and hospital or emergency visits. If confirmed in later development, these outcomes could support differentiation and expand the company’s respiratory pipeline opportunity.

Phase 2 Asthma Efficacy

Positive asthma data broaden the clinical case for rademikibart across related respiratory indications. The observed lung-function improvement and fewer treatment failures support continued development, while the reported placebo-comparable safety profile may help the program progress toward later-stage testing.

Low Debt Balance Sheet

Very low debt reduces fixed financing obligations and limits interest-related pressure while the company advances clinical programs. This gives management more flexibility than a highly leveraged balance sheet, although continued losses still make preservation of financial resources important.

Bears Say

Zero Revenue And Large Losses

The absence of revenue and substantial net losses show that the company has not yet established a durable commercial earnings base. Continued dependence on clinical progress rather than product sales leaves results vulnerable to development setbacks and limits internally generated funding.

Persistent Cash Burn

Persistent operating and free-cash-flow deficits require the company to fund research and corporate activities from existing resources or external capital. Unless spending falls or revenue is rebuilt, ongoing burn can restrict development choices and increase financing pressure over the coming quarters.

Nasdaq Bid-price Compliance Risk

The minimum bid-price notice creates an ongoing listing-compliance issue through the stated cure period, even though trading was not immediately affected. Failure to regain compliance could add operational distraction and market-access uncertainty while the company remains financially loss-making.

Connect Biopharma Holdings News

CNTB FAQ

What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.55 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $37.33M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 133 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Nov 16, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.008.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.19.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 64,488,300 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went down -10.109%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Hedge funds hold Connect Biopharma Holdings shares: the largest hedge-fund position in Connect Biopharma Holdings is 72,324,734 shares, and hedge funds increased their holdings by 871.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology